Medtronic (MDT) Earnings Date & Reports

Key Takeaways

• Medtronic reported first quarter fiscal 2027 revenue of $9.76 billion, up 13.7% year over year and above the roughly $9.55 billion consensus estimate.
• Adjusted earnings per share (EPS) reached $1.45, beating the $1.39 consensus forecast by $0.06 and up from $1.26 a year earlier.
• A 53-week fiscal year added an extra selling week in the quarter, contributing an estimated $570 million (about 670 basis points) to organic growth.
• Management raised full-year fiscal 2027 guidance to 7.25%–7.75% organic revenue growth and adjusted EPS of $5.94 to $6.00.
• Cardiac Ablation Solutions was a standout, growing 88% worldwide, while the U.S. Affera installed base rose more than 35% sequentially.
• For more on Medtronic, explore its Major News, Today's Price Move, Price Targets, and Forecast.
• Looking for automated ideas? Discover Trending AI Robots to see how AI-driven strategies are navigating the market.

Earnings Context and Why It Matters

Medtronic's first quarter fiscal 2027 results, reported for the period ended July 31, 2026, offer an important read on the medical device giant's momentum across its four operating segments. Coming off a fiscal 2027 in which management has emphasized newer growth platforms, the quarter tested whether double-digit growth could extend beyond a single flagship franchise. The results matter for investors because they reflect both the durability of core businesses like cardiac rhythm management and the early scaling of faster-growing areas such as cardiac ablation, robotics, and renal denervation. The broad-based beat and subsequent guidance raise signaled confidence in the company's execution heading into the rest of the fiscal year.

Reported Results

Medtronic delivered first quarter fiscal 2027 net sales of $9.76 billion, an increase of 13.7% on both a reported and organic basis from $8.58 billion in the prior-year quarter. GAAP net income attributable to Medtronic was $1.47 billion, or $1.14 per diluted share, up from $1.04 billion, or $0.81 per share, a year earlier. On an adjusted, non-GAAP (non-Generally Accepted Accounting Principles) basis, EPS came in at $1.45, exceeding the $1.39 consensus estimate by $0.06.

Segment performance was broad-based. Cardiovascular revenue rose 19.5% to $3.93 billion, Neuroscience grew 10.3% to $2.68 billion, Medical Surgical increased 10.0% to $2.28 billion, and Diabetes climbed 16.9% to $843 million. Adjusted operating margin improved 10 basis points to 23.7%. Management noted that an extra fiscal week contributed an estimated $570 million to organic growth.

Medtronic also raised its full-year outlook, lifting fiscal 2027 organic revenue growth guidance to 7.25%–7.75% (from 6.75%–7.25%) and adjusted EPS guidance to $5.94–$6.00 (from $5.90–$6.00).

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to refine your own research workflow.

Market Reaction and Investor Sentiment

Medtronic shares rose roughly 5% following the report, reflecting investor approval of the earnings beat and the upwardly revised guidance. The market's reaction was driven by the breadth of the performance, with growth across all four operating segments and particular strength in the higher-growth Cardiac Ablation Solutions franchise, which surpassed $2 billion in trailing 12-month revenue ahead of schedule. Investors also appeared encouraged by the company's commentary on emerging platforms, including the Hugo robotic surgery system and the Symplicity renal denervation business. The tempered note came from the one-time extra-week benefit, which will not repeat in subsequent quarters.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will watch whether Medtronic can sustain its momentum as the favorable extra-week comparison rolls off. Management's second quarter guidance implies a meaningful step-down in organic growth to roughly 6%, so confirming execution against that bar will be an early test of the raised full-year outlook.

Several catalysts deserve attention. The continued adoption of the Affera and Sphere-9 platforms in cardiac ablation will be central, along with progress in renal denervation and the Hugo robotics system. Gross margin remains a watch item, given the mix shift toward faster-growing but lower-margin businesses such as Diabetes and Cardiac Ablation Solutions.

Additionally, the planned separation of the Diabetes business is a key structural development to monitor, as it could reshape Medtronic's portfolio and long-term growth profile. Foreign exchange is expected to present a modest headwind for the full year, adding another variable to reported results. These factors, taken together, will shape how investors assess the durability of the company's fiscal 2027 trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations